Bardoxolone methyl (CDDO-Me) as a therapeutic agent: an update on its pharmacokinetic and pharmacodynamic properties.
about
Bypassing Mechanisms of Mitochondria-Mediated Cancer Stem Cells Resistance to Chemo- and RadiotherapyPharmacology and Clinical Drug Candidates in Redox MedicineAntioxidants in Translational MedicineMacrophage Migration Inhibitory Factor as an Emerging Drug Target to Regulate Antioxidant Response Element SystemRedox-based therapeutics in neurodegenerative disease.Bardoxolone methyl induces apoptosis and autophagy and inhibits epithelial-to-mesenchymal transition and stemness in esophageal squamous cancer cells.Hsp90 Is a Novel Target Molecule of CDDO-Me in Inhibiting Proliferation of Ovarian Cancer CellsBardoxolone Methyl Prevents Fat Deposition and Inflammation in Brown Adipose Tissue and Enhances Sympathetic Activity in Mice Fed a High-Fat DietNrf2 Signaling and the Slowed Aging Phenotype: Evidence from Long-Lived ModelsSynthetic Triterpenoid Inhibition of Human Ghrelin O-Acyltransferase: The Involvement of a Functionally Required Cysteine Provides Mechanistic Insight into Ghrelin Acylation.Direct Keap1-Nrf2 disruption as a potential therapeutic target for Alzheimer's disease.Abnormal Glucose Metabolism in Alzheimer's Disease: Relation to Autophagy/Mitophagy and Therapeutic ApproachesUremic Toxicity of Advanced Glycation End Products in CKD.Repurposing the NRF2 Activator Dimethyl Fumarate as Therapy Against Synucleinopathy in Parkinson's DiseaseNatural compound-derived epigenetic regulators targeting epigenetic readers, writers and erasers.CDDO-Me reveals USP7 as a novel target in ovarian cancer cells.Differential regulation of innate immune cytokine production through pharmacological activation of Nuclear Factor-Erythroid-2-Related Factor 2 (NRF2) in burn patient immune cells and monocytes.Collaborative Power of Nrf2 and PPARγ Activators against Metabolic and Drug-Induced Oxidative InjuryA unique tolerizing dendritic cell phenotype induced by the synthetic triterpenoid CDDO-DFPA (RTA-408) is protective against EAE.Oxidative stress serves as a key checkpoint for IL-33 release by airway epithelium.Nrf2 at the Heart of Oxidative Stress and Cardiac Protection.Emerging Therapeutics in Pulmonary Hypertension.Multimodal actions of the phytochemical sulforaphane suppress both AR and AR-V7 in 22Rv1 cells: Advocating a potent pharmaceutical combination against castration-resistant prostate cancer.Oleanolic Acid and Its Derivatives: Biological Activities and Therapeutic Potential in Chronic Diseases.Electrophilic fatty acid nitroalkenes regulate Nrf2 and NF-κB signaling:A medicinal chemistry investigation of structure-function relationships.Metabolic dysfunction in pulmonary hypertension: from basic science to clinical practice.The Nrf2 inhibitor brusatol is a potent antitumour agent in an orthotopic mouse model of colorectal cancer.Design and development of Nrf2 modulators for cancer chemoprevention and therapy: a reviewEssential Role of Keap1-Nrf2 Signaling in Mood Disorders: Overview and Future PerspectiveDesign, Synthesis, and Antiproliferative Evaluation of Novel Coumarin/2-Cyanoacryloyl Hybrids as Apoptosis Inducing Agents by Activation of Caspase-Dependent PathwayReactive Oxygen Species as Regulators of MDSC-Mediated Immune Suppression
P2860
Q26772300-CD6376A4-1FAF-4336-BD5D-B59EB6F7AF74Q26785525-5DF28D67-9274-4386-B28A-93E1D54C7AD7Q28394550-A96B7CFB-3F8C-4E6D-B5B6-0BA2A98D9A07Q28817936-D0ADC3CB-A586-496F-81C9-E612F92F507BQ34535918-18C6AF61-FD64-48F7-837C-4F81D4B9D605Q35115295-649679C2-4C48-4959-8691-0613C5711467Q35680729-3C25DFDA-D0AE-4212-B9CB-674A6E852976Q35808984-4FE514ED-44BB-424E-9DA2-3E7F26B7A61EQ36260040-83BEABF6-0CE7-48F1-A285-02818BBFA455Q36263619-D6BE8660-B8CC-496C-9132-B912DA775188Q36295178-3F307F7B-EDA8-4249-B26F-AE8F220DA8FBQ36359713-A45C1B82-70B1-488B-A295-DD5B8893B189Q36514906-0BAECC4C-4EF1-4D89-8E83-6BFF50E7BC63Q37091371-512905C7-6341-4A70-A533-D61F674552C0Q37114055-297EC867-2BB3-4D5E-A006-DABA64E9C8FDQ37718344-829CF9D7-E4A6-4C68-B4E9-CA7AC670AC71Q40060254-8747472B-3C89-4204-8D84-49D1F653CFE9Q41449206-1D66A8FF-B1C7-490D-AB36-0D97BB37D6ABQ41549202-EF122089-7184-459B-A469-80F26138122BQ46407290-C33DF0C2-F15C-490F-8EFD-42627F183100Q47350229-65764B9C-CC89-4168-A06F-22F74AC1CCAFQ47700134-1F900868-ABB4-491E-8E92-A01627438141Q47811299-F42230A7-B569-4484-A257-D8A04AB9DBA9Q48305370-3BD2F6CD-9576-455C-8172-6BAE432531C2Q49358694-1F49C16F-84E4-4201-8AA0-9B0876ABB373Q55112828-D8105100-7604-428A-BF0B-3C6AAD80441FQ55252442-84290D21-D044-4175-A1CA-FA8365D7AF75Q57069735-01760D3F-1BD9-4D5B-95C6-EEAF2D3B9657Q58554142-9E9853BB-FAD6-43AB-9CE0-3F7B79E75B03Q58697155-31239611-3F82-4FFD-82A3-7C66DD252912Q58698002-ED90A3E8-C74A-4345-A632-8E61E6D95359
P2860
Bardoxolone methyl (CDDO-Me) as a therapeutic agent: an update on its pharmacokinetic and pharmacodynamic properties.
description
2014 nî lūn-bûn
@nan
2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Bardoxolone methyl (CDDO-Me) a ...... nd pharmacodynamic properties.
@ast
Bardoxolone methyl (CDDO-Me) a ...... nd pharmacodynamic properties.
@en
Bardoxolone methyl
@nl
type
label
Bardoxolone methyl (CDDO-Me) a ...... nd pharmacodynamic properties.
@ast
Bardoxolone methyl (CDDO-Me) a ...... nd pharmacodynamic properties.
@en
Bardoxolone methyl
@nl
prefLabel
Bardoxolone methyl (CDDO-Me) a ...... nd pharmacodynamic properties.
@ast
Bardoxolone methyl (CDDO-Me) a ...... nd pharmacodynamic properties.
@en
Bardoxolone methyl
@nl
P2093
P2860
P356
P1476
Bardoxolone methyl (CDDO-Me) a ...... nd pharmacodynamic properties.
@en
P2093
Shu-Feng Zhou
Yan-Yang Wang
Yin-Xue Yang
P2860
P304
P356
10.2147/DDDT.S68872
P407
P577
2014-10-23T00:00:00Z